Scott Day New Telos Partners VP and General Manager

Day to Accelerate Growth Strategy

Telos Partners LLC, a subsidiary of OrthoPediatrics Corporation (NASDAQ: KIDS), specializing in the delivery of regulatory, reimbursement, and clinician adoption and other consulting services to the orthopedic, spine, and wound care industries, is pleased to welcome Scott Day to the position of Senior VP and General Manager.

Scott Day assumes this role following the completion of Jason Inzana’s time leading the Telos organization.

Since being acquired by OrthoPediatrics, Telos has more than doubled the size of its team, streamlined its sales channel, and expanded its client base. The firm is poised to compete in a market where this client base faces unprecedented challenges associated with market entrance, sustainment, and growth barriers around the world.

Scott is a medical technology veteran, uniquely equipped to lead the Telos team forward on this foundation. As Senior Vice President of the Orthofix US orthopedic business unit, his leadership resulted in 31% growth during his 4+ year tenure. In Scott’s most recent position, Executive VP and Chief Operating Officer at Gramercy Extremity Orthopedics, he led the implementation and adoption of the company’s proprietary sterile-packaged, RFID-enabled solutions in renowned surgery centers and Integrated Delivery Networks (IDNs).

“As planned, Jason’s leadership has set Telos on a strong foundation for predictable revenue contribution to OrthoPediatrics,” commented Joel Batts, Sr. Vice President of Science and Technology at OrthoPediatrics. “Scott now takes the baton and leads the team into an aggressive growth mode that never compromises on the Telos commitment to deliver high-quality outcomes to meet the clients’ ultimate objective. The consistent business growth he has achieved through inspiring medical technology teams to perform spans start-ups to multi-national companies over nearly 20 years. It is a great privilege to welcome Scott to Telos.”

“Telos has some of the brightest, most capable minds in the industry and I could not be more excited to lead the firm at this stage in its lifecycle,” said Mr. Day. “Knowing the challenges on the immediate horizon, such as how companies innovate within an increasingly arduous regulatory environment, the Telos team stands ready to address the unique needs of existing and future clients.”

 

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.